$0.36
2.26%
Nasdaq, Fri, Sep 06 2024
ISIN
US68232V3069
Symbol
ONTX
Sector
Industry

Onconova Therapeutics Inc. Stock price

$0.36
+0.01 2.64% 1M
-0.54 59.78% 6M
-0.38 51.45% YTD
-0.42 53.60% 1Y
-4.86 93.07% 3Y
-38.79 99.08% 5Y
-12,419.64 100.00% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.01 2.26%
ISIN
US68232V3069
Symbol
ONTX
Sector
Industry

Key metrics

Market capitalization $9.16m
Enterprise Value $103.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 451.70
P/S ratio (TTM) P/S ratio 39.83
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 0.00%
Revenue (TTM) Revenue $230.00k
EBIT (operating result TTM) EBIT $-20.65m
Free Cash Flow (TTM) Free Cash Flow $-23.19m
Cash position $16.89m
EPS (TTM) EPS $-5.53
P/E forward negative
P/S forward 40.18
EV/Sales forward 455.66
Short interest 0.10%
Show more

Is Onconova Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Onconova Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Onconova Therapeutics Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Onconova Therapeutics Inc. forecast:

Buy
100%

Financial data from Onconova Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.23 0.23
0% 0%
100%
- Direct Costs 0.02 0.02
100% 100%
9%
0.21 0.21
0% 0%
91%
- Selling and Administrative Expenses 10 10
20% 20%
4,383%
- Research and Development Expense 11 11
23% 23%
4,678%
-21 -21
7% 7%
-8,970%
- Depreciation and Amortization 0.02 0.02
100% 100%
9%
EBIT (Operating Income) EBIT -21 -21
7% 7%
-8,977%
Net Profit -137 -137
558% 558%
-59,587%

In millions USD.

Don't miss a Thing! We will send you all news about Onconova Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Onconova Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
5 months ago
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).
Neutral
GlobeNewsWire
6 months ago
NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further char...
Neutral
GlobeNewsWire
9 months ago
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors Data support the potential use of narazaciclib in breast and ovarian cancers Narazaciclib progressing towards RP2D and preparation for registrational studies, with...
More Onconova Therapeutics Inc. News

Company Profile

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Head office United States
CEO Werner Cautreels
Employees 17
Founded 1998
Website www.trawspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today